Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.

Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.